Case Study: a global pharmaceutical company accelerates migraine insights with Kantar's longitudinal patient registry

Our client needed to understand how the introduction of new treatments influences healthcare delivery, prescribing/use, and the impact on migraine patients

The global pharma company needed to understand how new treatments impact healthcare delivery and migraine patient care in an extremely crowded market. They partnered with Kantar, which utilized a longitudinal patient registry service, to gain a robust understanding of the therapeutic category as they prepared to launch a new class of medication.

Kantar executed a two-year study tracking 40,000 patients, supplying critical data on medication changes over time. This approach accelerated the client's decision-making, improved their engagements with payers and providers, and informed advertising campaigns. The impactful study also resulted in 16 accepted conference abstracts and over five manuscripts in process for the medical community.